Abstract
Objective: The aim of this paper was to highlight the mechanisms involved and the relationship between depression and psoriasis. Method: A comprehensive literature search was performed in various databases, and finally 88 studies were deemed relevant. Results: A significant link was found between depression and psoriasis, primarily through immune mechanisms related but not limited to the actions of inflammatory cytokines such as tumor necrosis factor-α, interleukin 1 (IL-1), IL-2, IL-10, interferon-γ, IL-1β, prostaglandin E2, C-reactive protein, IL-6, and IL-8. Conclusion: Various neuroimmunological studies point towards the notion that depression and psoriasis are associated with each other. Melatonin has also been found to be associated with both conditions. A possibility exists that both conditions can cause each other due to the possible bidirectional relationship of psoriasis and major depression. However, if this is the case, then why all depressed patients fail to develop psoriasis and why all psoriatic patients fail to develop depression remains a question unanswered. We believe that future studies will unmask this mystery.
References
1.
Levenson, James L: Essentials of Psychosomatic Medicine. Arlington, American Psychiatric Press, 2006.
2.
Brown GE, Malakouti M, Sorenson E, Gupta R, Koo JY: Psychodermatology. Adv Psychosom Med 2015;34:123-134.
3.
Leon A, Levin EC, Koo JY: Psychodermatology: an overview. Semin Cutan Med Surg 2013;32:64-67.
4.
Questions and Answers about Psoriasis. National Institute of Arthritis and Musculoskeletal and Skin Diseases. October 2013. http://www.niams.nih.gov/health_info/psoriasis/.
5.
Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R: Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-850.
6.
Lebwohl M: Psoriasis. Lancet 2003;361:1197-1204.
7.
Chong HT, Kopecki Z, Cowin AJ: Lifting the silver flakes: the pathogenesis and management of chronic plaque psoriasis. Biomed Res Int 2013;2013:168321.
8.
Huerta C, Rivero E, Garcia Rodriguez LA: Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007;143:1559-1565.
9.
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated Comorbidity (IMPACT) project team: Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013;133:377-385.
10.
Krishnadas R, Nicol A, Sassarini J, Puri N, Burden AD, Leman J, Combet E, Pimlott S, Hadley D, McInnes IB, Cavanagh J: Circulating tumour necrosis factor is highly correlated with brainstem serotonin transporter availability in humans. Brain Behav Immun 2016;51:29-38.
11.
White JR, Chang CH, So-Armah KA, Stewart JC, Gupta SK, Butt AA, Gibert CL, Rimland D, Rodriguez-Barradas MC, Leaf DA, Bedimo RJ, Gottdiener JS, Kop WJ, Gottlieb SS, Budoff MJ, Khambaty T, Tindle H, Justice AC, Freiberg MS: Depression and HIV Infection are Risk Factors for Incident Heart Failure Among Veterans: Veterans Aging Cohort Study. Circulation 2015;132:1630-1638.
12.
Bisschop MI, Kriegsman DM, Deeg DJ, Beekman AT, van Tilburg W: The longitudinal relation between chronic diseases and depression in older persons in the community: the Longitudinal Aging Study Amsterdam. J Clin Epidemiol 2004;57:187-194.
13.
Krishnan KR, Delong M, Kraemer H, Carney R, Spiegel D, Gordon C, McDonald W, Dew M, Alexopoulos G, Buckwalter K, Cohen PD, Evans D, Kaufmann PG, Olin J, Otey E, Wainscott C: Comorbidity of depression with other medical diseases in the elderly. Biol Psychiatry 2002;52:559-588.
14.
Nicholson A, Kuper H, Hemingway H: Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6,362 events among 146,583 participants in 54 observational studies. Eur Heart J 2006;27:2763-2774.
15.
Nasir U, Shahid H, Shabbir MO: Sleep quality and depression in hospitalized congestive heart failure patients. J Pak Med Assoc 2015;65:264-269.
16.
Akay A, Pekcanlar A, Bozdag KE, Altintas L, Karaman A: Assessment of depression in subjects with psoriasis vulgaris and lichen planus. J Eur Acad Dermatol Venereol 2002;16:347-352.
17.
Esposito M, Saraceno R, Giunta A, Maccarone M, Chimenti S: An Italian study on psoriasis and depression. Dermatology 2006;212:123-127.
18.
Gupta MA, Gupta AK, Kirkby S, Schork NJ, Gorr SK, Ellis CN, Voorhees JJ: A psychocutaneous profile of psoriasis patients who are stress reactors. A study of 127 patients. Gen Hosp Psychiatry 1989;11:166-173.
19.
Gupta MA, Gupta AK, Schork NJ, Ellis CN: Depression modulates pruritus perception: a study of pruritus in psoriasis, atopic dermatitis, and chronic idiopathic urticaria. Psychosom Med 1994;56:36-40.
20.
Fordham B, Griffiths CE, Bundy C: A pilot study examining mindfulness-based cognitive therapy in psoriasis. Psychol Health Med 2015;20:121-127.
21.
Polenghi MM, Molinari E, Gala C, Guzzi R, Garutti C, Finzi AF: Experience with psoriasis in a psychosomatic dermatology clinic. Acta Derm Venereol Suppl (Stockh) 1994;186:65-66.
22.
Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani P: The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol 2010;62:812-818.
23.
Fortune DG, Richards HL, Kirby B, Bowcock S, Main CJ, Griffiths CE: A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol 2002;146:458-465.
24.
Mease PJ, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM: Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials. Dermatology 2010;220:1-7.
25.
Redighieri IP, Maia Tde C, Nadal MA, Caliman TR, Ruiz Mde F, Petri V: Erythrodermic psoriasis with regression after prophylaxis with isoniazid and antidepressant therapy: case report. An Bras Dermatol 2011;86(4 suppl 1):S141-S143.
26.
Van Voorhees AS, Fried R: Depression and quality of life in psoriasis. Postgrad Med 2009;121:154-161.
27.
Palfreeman AC, McNamee KE, McCann FE: New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. Drug Des Devel Ther 2013;7:201-210.
28.
Cedeno-Laurent F, Gómez-Flores M, Mendez N, Ancer-Rodríguez J, Bryant JL, Gaspari AA, Trujillo JR: New insights into HIV-1 primary skin disorders. J Int AIDS Soc 2011;14:5.
29.
Nestle FO, Kaplan DH, Barker J: Psoriasis. N Engl J Med 2009;361:496-509.
30.
Ouyang W: Distinct roles of IL-22 in human psoriasis and inflammatory bowel disease. Cytokine Growth Factor Rev 2010;21:435-441.
31.
Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ: The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 1993;101:701-715.
32.
Raychaudhuri SK, Maverakis E, Raychaudhuri SP: Diagnosis and classification of psoriasis. Autoimmun Rev 2014;13:490-495.
33.
Parrish L: Psoriasis: symptoms, treatments and its impact on quality of life. Br J Community Nurs 2012;17:524, 526, 528.
34.
Brunoni AR, Lotufo PA, Sabbag C, Goulart AC, Santos IS, Benseñor IM: Decreased brain-derived neurotrophic factor plasma levels in psoriasis patients. Braz J Med Biol Res 2015;48:711-714.
35.
Kim J, Bissonnette R, Lee J, Correa da Rosa J, Suárez-Fariñas M, Lowes MA, Krueger JG: The spectrum of mild-to-severe psoriasis vulgaris is defined by a common activation of IL-17 pathway genes, but with key differences in immune regulatory genes. J Invest Dermatol 2016, DOI: 10.1016/j.jid.2016.04.032, Epub ahead of print.
36.
Speeckaert R, Lambert J, Grine L, Van Gele M, De Schepper S, van Geel N: The many faces of IL-17 in inflammatory skin diseases. Br J Dermatol 2016, DOI: 10.1111/bjd.14703, Epub ahead of print.
37.
Wong ML, Dong C, Maestre-Mesa J, Licinio J: Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response. Mol Psychiatry 2008;13:800-812.
38.
Miller AH, Maletic V, Raison CL: Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2008;65:732-741.
39.
Miller AH, Raison CL: Immune system contributions to the pathophysiology of depression. Focus (Am Psychiatr Publ) 2008;6:36-45.
40.
Motivala SJ, Sarfatti A, Olmos L, Irwin MR: Inflammatory markers and sleep disturbance in major depression. Psychosom Med 2005;67:187-194.
41.
Rosenblat JD, Cha DS, Mansur RB, McIntyre RS: Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog Neuropsychopharmacol Biol Psychiatry 2014;53:23-34.
42.
McNally L, Bhagwagar Z, Hannestad J: Inflammation, glutamate, and glia in depression: a literature review. CNS Spectr 2008;13:501-510.
43.
Moon H, Mizara A, McBride SR: Psoriasis and psycho-dermatology. Dermatol Ther (Heidelb) 2013;3:117-130.
44.
Kannan S, Heller MM, Lee ES, Koo JY: The role of tumor necrosis factor-α and other cytokines in depression: what dermatologists should know. J Dermatolog Treat 2013;24:148-152.
45.
Alesci S, Martinez PE, Kelkar S, Ilias I, Ronsaville DS, Listwak SJ, Ayala AR, Licinio J, Gold HK, Kling MA, Chrousos GP, Gold PW: Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. J Clin Endocrinol Metab 2005;90:2522-2530.
46.
Miller GE, Stetler CA, Carney RM, Freedland KE, Banks WA: Clinical depression and inflammatory risk markers for coronary heart disease. Am J Cardiol 2002;90:1279-1283.
47.
Bouhuys AL, Flentge F, Oldehinkel AJ, van den Berg MD: Potential psychosocial mechanisms linking depression to immune function in elderly subjects. Psychiatry Res 2004;127:237-245.
48.
Musselman DL, Miller AH, Porter MR, Manatunga A, Gao F, Penna S, Pearce BD, Landry J, Glover S, McDaniel JS, Nemeroff CB: Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry 2001;158:1252-1257.
49.
Kahl KG, Rudolf S, Stoeckelhuber BM, Dibbelt L, Gehl HB, Markhof K, Hohagen F, Schweiger U: Bone mineral density, markers of bone turnover, and cytokines in young women with borderline personality disorder with and without comorbid major depressive disorder. Am J Psychiatry 2005;162:168-174.
50.
Tiemeier H, Hofman A, van Tuijl HR, Kiliaan AJ, Meijer J, Breteler MM: Inflammatory proteins and depression in the elderly. Epidemiology 2003;14:103-107.
51.
Schlatter J, Ortuño F, Cervera-Enguix S: Monocytic parameters in patients with dysthymia versus major depression. J Affect Disord 2004;78:243-247.
52.
Ford DE, Erlinger TP: Depression and C-reactive protein in US adults. Arch Intern Med 2004;164:1010-1014.
53.
Danner M, Kasl SV, Abramson JL, Vaccarino V: Association between depression and elevated C-reactive protein. Psychosom Med 2003;65:347-356.
54.
Maes M: Major depression and activation of the inflammatory response system. Adv Exp Med Biol 1999;461:25-46.
55.
Levine J, Barak Y, Chengappa KN, Rapoport A, Rebey M, Barak V: Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 1999;40:171-176.
56.
Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H: Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000;22:370-379.
57.
Rajagopalan S, Brook R, Rubenfire M, Pitt E, Young E, Pitt B: Abnormal brachial artery flow-mediated vasodilation in young adults with major depression. Am J Cardiol 2001;88:196-198.
58.
Sluzewska A, Rybakowski JK, Laciak M, Mackiewicz A, Sobieska M, Wiktorowicz K: Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann NY Acad Sci 1995;762:474-476.
59.
Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H: Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997;9:853-858.
60.
Mikova O, Yakimova R, Bosmans E, Kenis G, Maes M: Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol 2001;11:203-208.
61.
Sluzewska A, Sobieska M, Rybakowski JK: Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. Neuropsychobiology 1997;35:123-127.
62.
Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E: Increased serum tumor necrosis factor- α levels and treatment response in major depressive disorder. Psychopharmacology (Berl) 2003;170:429-433.
63.
Hestad KA, Tønseth S, Støen CD, Ueland T, Aukrust P: Raised plasma levels of tumor necrosis factor alpha in patients with depression. J ECT 2003;19:183-188.
64.
Owen BM, Eccleston D, Ferrier IN, Young AH: Raised levels of plasma interleukin-1beta in major and postviral depression. Acta Psychiatr Scand 2001;103:226-228.
65.
Thomas AJ, Davis S, Morris C, Jackson E, Harrison R, OʼBrien JT: Increase in interleukin-1β in late-life depression. Am J Psychiatry 2005;162:175-177.
66.
Raison CL, Capuron L, Miller AH: Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006;27:24-31.
67.
Beretta L, Cossu M, Marchini M, Cappiello F, Artoni A, Motta G, Scorza R: A polymorphism in the human serotonin 5-HT2A receptor gene may protect against systemic sclerosis by reducing platelet aggregation. Arthritis Res Ther 2008;10:R103.
68.
Ni C, Chiu MW: Psoriasis and comorbidities: links and risks. Clin Cosmet Investig Dermatol 2014;7:119-132.
69.
Schiepers OJ, Wichers MC, Maes M: Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:201-217.
70.
Maes M, Kubera M, Obuchowiczwa E, Goehler L, Brzeszcz J: Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative and nitrosative stress pathways. Neuro Endocrinol Lett 2011;32:7-24.
71.
Al'Abadie MS, Kent GG, Gawkrodger DJ: The relationship between stress and the onset and exacerbation of psoriasis and other skin conditions. Br J Dermatol 1994;130:199-203.
72.
Devrimci-Ozguven H, Kundakci TN, Kumbasar H, Boyvat A: The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J Eur Acad Dermatol Venereol 2000;14:267-271.
73.
Magin P, Adams J, Heading G, Pond D, Smith W: Experiences of appearance-related teasing and bullying in skin diseases and their psychological sequelae: results of a qualitative study. Scand J Caring Sci 2008;22:430-436.
74.
Fava GA, Perini GI, Santonastaso P, Fornasa CV: Life events and psychological distress in dermatologic disorders: psoriasis, chronic urticaria and fungal infections. Br J Med Psychol 1980;53:277-282.
75.
Gupta MA, Schork NJ, Gupta AK, Kirkby S, Ellis CN: Suicidal ideation in psoriasis. Int J Dermatol 1993;32:188-190.
76.
Hardy GE, Cotterill JA: A study of depression and obsessionality in dysmorphophobic and psoriatic patients. Br J Psychiatry 1982;140:19-22.
77.
Breuer K, Göldner FM, Jäger B, Werfel T, Schmid-Ott G: Relationship between chronic stress and CRP levels in women with psoriasis. J Dtsch Dermatol Ges 2016;14:528-530.
78.
Schmid-Ott G, Jaeger B, Boehm T, Langer K, Stephan M, Raap U, Werfel T: Immunological effects of stress in psoriasis. Br J Dermatol 2009;160:782-785.
79.
Kartha LB, Chandrashekar L, Rajappa M, Menon V, Thappa DM, Ananthanarayanan PH: Serum melatonin levels in psoriasis and associated depressive symptoms. Clin Chem Lab Med 2014;52:1-3.
80.
Sandyk R, Pardeshi R: Mood-dependent fluctuations in the severity of tardive dyskinesia and psoriasis vulgaris in a patient with schizoaffective disorder: possible role of melatonin. Int J Neurosci 1990;50:215-221.
81.
Carrillo-Vico A, Lardone PJ, Alvarez-Sánchez N, Rodríguez-Rodríguez A, Guerrero JM: Melatonin: buffering the immune system. Int J Mol Sci 2013;14:8638-8683.
82.
Esposito E, Cuzzocrea S: Anti-inflammatory activity of melatonin in central nervous system. Curr Neuropharmacol 2010;8:228-242.
83.
Mozzanica N, Tadini G, Radaelli A, Negri M, Pigatto P, Morelli M, Frigerio U, Finzi A, Esposti G, Rossi D, et al: Plasma melatonin levels in psoriasis. Acta Derm Venereol 1988;68:312-316.
84.
Diffey BL: Ultraviolet radiation physics and the skin. Phys Med Biol 1980;25:405-426.
85.
Golpour M, Hosseini SH, Khademloo M, Ghasemi M, Ebadi A, Koohkan F, Shahmohammadi S: Depression and anxiety disorders among patients with psoriasis: a hospital-based case-control study. Dermatol Res Pract 2012;2012:381905.
86.
Dalgard FJ, Gieler U, Tomas-Aragones L, Lien L, Poot F, Jemec GB, Misery L, Szabo C, Linder D, Sampogna F, Evers AW, Halvorsen JA, Balieva F, Szepietowski J, Romanov D, Marron SE, Altunay IK, Finlay AY, Salek SS, Kupfer J: The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol 2015;135:984-991.
87.
Demirhan O, Demirbek B, Tunç E, Uslu IN, Çetiner S, Serin A: Identification of chromosome abnormalities in screening of a family with manic depression and psoriasis: predisposition to aneuploidy. Asian J Psychiatr 2012;5:169-174.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
